The Impact of Exercise on Stress, Fatigue, and Quality of Life in Individuals With Primary Immunodeficiency Disease
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03211689 |
Recruitment Status :
Completed
First Posted : July 7, 2017
Last Update Posted : September 6, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Primary Immune Deficiency Disorder Common Variable Immunodeficiency Specific Antibody Deficiency Hypergammaglobulinemia | Other: Exercise Program | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 36 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | The Impact of Exercise on Stress, Fatigue, and Quality of Life in Individuals With Primary Immunodeficiency Disease |
Actual Study Start Date : | June 27, 2017 |
Actual Primary Completion Date : | December 31, 2017 |
Actual Study Completion Date : | December 31, 2017 |

Arm | Intervention/treatment |
---|---|
Experimental: Exercise Group
Participants will engage in up to 150 minutes of exercise per week, at a level of 11-14 on the Borg Rate of Perceived Exertion scale.
|
Other: Exercise Program
Participants will utilize the Physitrack exercise program to engage in up to 150 minutes of exercise at a rating of 11-14 on the Borg Rate of Perceived Exertion scale, per week. |
No Intervention: Control Group
Participants will continue normal activities, with no new participation in exercise program (may engage in less than 75 minutes of non-structured exercise per week).
|
- Short Form 36 version 2 [ Time Frame: Change during 8 weeks ]Measure of quality of life.
- Infection Incidence [ Time Frame: Change from 8 weeks prior to the start of study to the 8 weeks during the study ]Measure of number of infections that have occurred
- Unplanned use of medical provider [ Time Frame: Change from 8 weeks prior to the start of the study to the 8 weeks during the study. ]Number of unplanned visits to a medical provider
- Fatigue Impact Scale [ Time Frame: Change during 8 weeks ]Measure of fatigue.
- Exercise Benefits/Barriers Scale [ Time Frame: Change during 8 weeks ]Measure of perceptions about exercise.
- Perceived Stress Scale 10 [ Time Frame: Change during 8 weeks ]Measure of stress.
- Self-efficacy for Exercise Scale [ Time Frame: Change during 8 weeks ]Measure about ability to comply with exercise program
- Subjective Exercise Experience Scale [ Time Frame: Change during 8 weeks ]Measures perceptions about participation in an exercise program

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- 18 years of age or older.
- Physician diagnosis of a primary immunodeficiency disease (as evidenced by physician letter or medical documentation/report)
- Willingness to participate in eight-week exercise program
Exclusion Criteria:
- Current participation in a structured exercise program for greater than 75 minutes per week
- Any medical condition that prevents participation in a low to moderate level exercise program (such as, but not limited to, uncontrolled asthma, unstable cardiac condition, acute orthopedic injury which requires restricted activities)

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03211689
United States, New Jersey | |
Stockton University | |
Galloway, New Jersey, United States, 08205 |
Principal Investigator: | Kerri Sowers, PT, DPT, NCS | Stockton University |
Responsible Party: | Kerri Sowers PT, DPT, NCS, Assistant Professor of Health Science, Stockton University |
ClinicalTrials.gov Identifier: | NCT03211689 |
Other Study ID Numbers: |
IRB00010183 IRB00002823 ( Other Identifier: Nova Southeastern University ) |
First Posted: | July 7, 2017 Key Record Dates |
Last Update Posted: | September 6, 2018 |
Last Verified: | September 2018 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Exercise Stress Fatigue Quality of Life |
Hypergammaglobulinemia Immunologic Deficiency Syndromes Common Variable Immunodeficiency Fatigue |
Immune System Diseases Blood Protein Disorders Hematologic Diseases Immunoproliferative Disorders |